BCHT(SH:688276) Ge Long Hui A P P·2025-10-13 09:34Core Viewpoint - The company has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant), targeting individuals aged 60 and above, which aims to enhance immune response [1] Group 1: Vaccine Development - The trivalent influenza virus split vaccine (BK-01 adjuvant) is developed in-house by the company, utilizing a split virus technology route combined with a self-developed adjuvant to ensure safety while improving immunogenicity [1] - Compared to traditional split influenza vaccines, this new vaccine is designed to stimulate a higher level of protective antibodies, providing effective protection for the elderly population [1] Group 2: Market Implications - If the vaccine successfully completes clinical trials and receives market approval, it will enhance the company's influenza vaccine development pipeline, offering new vaccination options for individuals aged 60 and above [1] - This development is expected to expand the company's coverage in the influenza vaccine market, optimize product structure, and contribute to the overall growth of its main business, thereby strengthening long-term profitability [1]